Patent 7623232 was granted and assigned to Chemimage Corporation on November, 2009 by the United States Patent and Trademark Office.
A method of ablating a viable biological pathogen in a sample. A viable biological pathogen in a portion of the sample is identified by irradiating the sample; assessing radiation scattered from the sample for radiation that exhibits a Raman shift characteristic of the viable biological pathogen, and delivering an ablating agent to the identified portion.